[go: up one dir, main page]

DE60023747D1 - Hydantoin-, thiohydantoin-, pyrimidinedion- und thioxopyrimidinon-derivate, verfahren zur ihrer herstellung und ihre anwendung als arztneimittel - Google Patents

Hydantoin-, thiohydantoin-, pyrimidinedion- und thioxopyrimidinon-derivate, verfahren zur ihrer herstellung und ihre anwendung als arztneimittel

Info

Publication number
DE60023747D1
DE60023747D1 DE60023747T DE60023747T DE60023747D1 DE 60023747 D1 DE60023747 D1 DE 60023747D1 DE 60023747 T DE60023747 T DE 60023747T DE 60023747 T DE60023747 T DE 60023747T DE 60023747 D1 DE60023747 D1 DE 60023747D1
Authority
DE
Germany
Prior art keywords
thioxopyrimidinone
pyrimidinedion
thiohydantoin
hydantoin
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60023747T
Other languages
English (en)
Other versions
DE60023747T2 (de
Inventor
Lydie Poitout
Christophe Thurieau
Valerie Brault
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS filed Critical Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Application granted granted Critical
Publication of DE60023747D1 publication Critical patent/DE60023747D1/de
Publication of DE60023747T2 publication Critical patent/DE60023747T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
DE60023747T 1999-07-30 2000-07-28 Hydantoin-, thiohydantoin-, pyrimidinedion- und thioxopyrimidinon-derivate, verfahren zur ihrer herstellung und ihre anwendung als arztneimittel Expired - Lifetime DE60023747T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9909886 1999-07-30
FR9909886A FR2796945B1 (fr) 1999-07-30 1999-07-30 Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
PCT/FR2000/002164 WO2001009090A2 (fr) 1999-07-30 2000-07-28 Derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinoneses, leurs procedes de preparation et leur application a titre de medicaments

Publications (2)

Publication Number Publication Date
DE60023747D1 true DE60023747D1 (de) 2005-12-08
DE60023747T2 DE60023747T2 (de) 2006-08-03

Family

ID=9548689

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60023747T Expired - Lifetime DE60023747T2 (de) 1999-07-30 2000-07-28 Hydantoin-, thiohydantoin-, pyrimidinedion- und thioxopyrimidinon-derivate, verfahren zur ihrer herstellung und ihre anwendung als arztneimittel

Country Status (24)

Country Link
US (3) US6759415B1 (de)
EP (1) EP1246807B1 (de)
JP (1) JP2003518011A (de)
KR (1) KR100712587B1 (de)
CN (1) CN1177828C (de)
AR (1) AR024939A1 (de)
AT (1) ATE308525T1 (de)
AU (1) AU779357B2 (de)
BR (1) BR0012852A (de)
CA (1) CA2380070C (de)
CZ (1) CZ2002301A3 (de)
DE (1) DE60023747T2 (de)
DK (1) DK1246807T3 (de)
ES (1) ES2252051T3 (de)
FR (1) FR2796945B1 (de)
HK (1) HK1052510B (de)
HU (1) HUP0202989A3 (de)
IL (1) IL147744A0 (de)
MX (1) MXPA02001016A (de)
NO (1) NO323605B1 (de)
NZ (1) NZ516718A (de)
PL (1) PL364726A1 (de)
RU (1) RU2277093C2 (de)
WO (1) WO2001009090A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011071D0 (en) * 2000-05-08 2000-06-28 Novartis Ag Organic compounds
JP4711523B2 (ja) * 2001-02-13 2011-06-29 日本臓器製薬株式会社 低アルブミン血症改善剤
CZ20033123A3 (cs) * 2001-06-25 2004-11-10 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farmaceutické prostředky, které inhibují proliferaci adenomů hypofýzy
FR2832710B1 (fr) * 2001-11-28 2004-09-03 Sod Conseils Rech Applic Derives de 5-sulfanyl-4h-1,2,4-triazoles et leur utilisation en tant que medicaments
MY133406A (en) * 2001-11-28 2007-11-30 Ipsen Pharma Sas 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as a medicament
US7189856B2 (en) 2001-12-28 2007-03-13 Gideon Shapiro Non-peptide somatostatin receptor ligands
HRP20050053A2 (en) * 2002-09-19 2005-04-30 Solvay Pharmaceuticals B.V. 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands
US7354933B2 (en) * 2003-01-31 2008-04-08 Aventis Pharma Sa Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
DE10325813B4 (de) 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
EP1621539A1 (de) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Heterocyclische-substituirte cyclische Harnstoffderivate, Verfaren zu ihrer Herstellung, und ihre pharmaceutische Verwendung als Kinase Inhibitoren
EP1621536A1 (de) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Amino zyklische Urea-Derivaten, ihre Herstellung und deren pharmazeutische Verwendungen als Kinase Inhibitoren
EP1621535A1 (de) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Cyclische Substituirte Harnstoffderivate, Verfahren zu ihrer Herstellung, und ihre pharmazeutische Verwendung als Kinase Inhibitoren
RS53967B1 (sr) * 2005-05-13 2015-08-31 The Regents Of The University Of California Diaril hidantoin jedinjenja kao antagonisti receptora androgena za lečenje raka
FR2896504B1 (fr) * 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
FR2896503B1 (fr) * 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
BRPI0715160A2 (pt) * 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
NZ590631A (en) 2006-09-21 2011-12-22 Probiodrug Ag Novel genes related to glutaminyl cyclase
US9277737B2 (en) 2006-09-21 2016-03-08 Probiodrug Ag Mouse models carrying a knock-out mutation of the QPCTL-gene
US8889709B2 (en) 2006-09-21 2014-11-18 Probiodrug Ag Use of isoQC inhibitors in the treatment and prevention of inflammatory diseases or conditions
EP2416657A4 (de) 2009-04-09 2012-09-05 Medivation Prostate Therapeutics Inc Substituierte di-arylhydantoin- und di-arylthiohydantoinverbindungen sowie verfahren für ihre verwendung
WO2013068875A1 (en) * 2011-11-11 2013-05-16 Pfizer Inc. 2-thiopyrimidinones
EP3188729A1 (de) * 2014-09-03 2017-07-12 Genzyme Corporation Cyclische harnstoffverbindungen als tropomyosinassoziierte kinase (trk)-inhibitoren
CN117120436A (zh) * 2021-03-30 2023-11-24 苏州开拓药业股份有限公司 一种一步法合成乙内酰硫脲衍生物的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
WO1997043278A1 (en) * 1996-05-14 1997-11-20 Novo Nordisk A/S Somatostatin agonists and antagonists
WO1998013045A1 (en) * 1996-09-24 1998-04-02 Taiho Pharmaceutical Co., Ltd. Cancerous metastasis inhibitors containing uracil derivatives
US6025372A (en) * 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
DK1019050T3 (da) * 1997-06-24 2002-07-08 Novo Nordisk As Anvendelse af somatostatinagonister og -antagonister til behandling af sygdomme i forbindelse med øjet
RU2263111C2 (ru) * 1998-06-12 2005-10-27 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик Сас Имидазольные производные
ES2188184T3 (es) * 1998-06-12 2003-06-16 Sod Conseils Rech Applic Compuestos de beta-carbolinas.
RU2242481C2 (ru) 1998-06-16 2004-12-20 Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик Сас Аналоги циклического соматостатина

Also Published As

Publication number Publication date
WO2001009090A3 (fr) 2002-08-08
NO323605B1 (no) 2007-06-18
BR0012852A (pt) 2002-04-30
AU779357B2 (en) 2005-01-20
US7199145B2 (en) 2007-04-03
US6759415B1 (en) 2004-07-06
MXPA02001016A (es) 2002-08-12
KR20020025203A (ko) 2002-04-03
HUP0202989A2 (hu) 2002-12-28
DE60023747T2 (de) 2006-08-03
NO20020463D0 (no) 2002-01-29
ATE308525T1 (de) 2005-11-15
RU2277093C2 (ru) 2006-05-27
NO20020463L (no) 2002-02-13
US7332517B2 (en) 2008-02-19
CN1399631A (zh) 2003-02-26
CA2380070A1 (fr) 2001-02-08
KR100712587B1 (ko) 2007-05-02
HUP0202989A3 (en) 2003-02-28
PL364726A1 (en) 2004-12-13
EP1246807A2 (de) 2002-10-09
FR2796945A1 (fr) 2001-02-02
IL147744A0 (en) 2002-08-14
HK1052510B (zh) 2005-04-29
CN1177828C (zh) 2004-12-01
US20040209908A1 (en) 2004-10-21
AU7009100A (en) 2001-02-19
CZ2002301A3 (cs) 2002-08-14
DK1246807T3 (da) 2006-03-20
CA2380070C (fr) 2010-11-09
NZ516718A (en) 2003-04-29
HK1052510A1 (en) 2003-09-19
ES2252051T3 (es) 2006-05-16
WO2001009090A2 (fr) 2001-02-08
AR024939A1 (es) 2002-10-30
JP2003518011A (ja) 2003-06-03
US20070021420A1 (en) 2007-01-25
EP1246807B1 (de) 2005-11-02
FR2796945B1 (fr) 2002-06-28

Similar Documents

Publication Publication Date Title
DE60023747D1 (de) Hydantoin-, thiohydantoin-, pyrimidinedion- und thioxopyrimidinon-derivate, verfahren zur ihrer herstellung und ihre anwendung als arztneimittel
ATE302754T1 (de) Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE60036294D1 (de) Umgossener transponder und verfahren zu dessen herstellung
DE60023023T2 (de) Zirkoniumdioxidsol und verfahren zu seiner herstellung
DE60027698D1 (de) Lasttragendes osteoimplantat und verfahren zu seiner herstellung
DE69724142D1 (de) Sulfonamid-derivate, verfahren zur ihrer herstellung und ihre verwendung als arzneimittel
DE50102147D1 (de) Acylphenylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE288577T1 (de) Ladeluftkühler und verfahren zu dessen herstellung
DE60313602D1 (de) N-iPHENYL(PIPERIDIN-2-YL)METHYLöBENZAMIDDERIVATE,VERFAHREN ZU IHRER HERSTELLUNG UND IHRE THERAPEUTISCHE ANWENDUNG
DE50004342D1 (de) Verbundlaminat und verfahren zu seiner herstellung
DE60103395D1 (de) 1,4-diazabicyclo[3.2.2]nonanbenzoxazol-, benzothiazol- und benzoimidazolderivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung
DE69920932D1 (de) Zylindrischer gegenstand mit fixiertem einsatzstück, sowie verfahren und gerät zu dessen herstellung
DE50011818D1 (de) Hochkratzfeste mehrschichtlackierung, verfahren zu ihrer herstellung und ihre verwendung
ATA206299A (de) Drosselrückschlagventil und verfahren zu dessen herstellung
DE50011179D1 (de) Aminocarbonyl-substituierte benzimidazolderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE50010354D1 (de) Verbundteil und verfahren zu dessen herstellung
DE59912402D1 (de) Polycyclische thiazolidin-2-yliden amine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE10081263D2 (de) Schraubverbindung und Verbindungsmittel hierfür sowie Verfahren zu deren Herstellung
DE60038384D1 (de) Polyarylen und verfahren zu dessen herstellung
DE60009415D1 (de) Korrosionsbeständiges Bauteil und Verfahren zu dessen Herstellung
DE60026045D1 (de) Schmierstoff und verfahren zu dessen herstellung
EP1152127A4 (de) Hohles hubventil und verfahren zu seiner herstellung
DE60029441D1 (de) Fadenbündel und verfahren zur dessen herstellung
ATE222584T1 (de) Biphenylsulfonylcyanamide, verfahren zu ihrer herstellung und ihre verwendung als medikament
DE50004252D1 (de) Transdermales therapeutisches system und verfahren zu seiner herstellung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: IPSEN PHARMA S.A.S., BOULOGNE-BILLANCOURT, FR